Clinical application of a contingent screening strategy for trisomies with cell-free DNA: A pilot study

Keyphrases

• Clinical Application 100%
• Cell-free DNA (cfDNA) 100%
• Cell-free DNA Screening 100%
• Screening Strategy 100%
• Contingent Screening 100%
• Detection Rate 66%
• Intermediate Risk 66%
• False Positive Rate 66%
• Trisomy 21 50%
• Trisomy 13 50%
• Trisomy 18 50%
• High Risk 33%
• Low Risk 33%
• Quadruple Test 33%
• First-trimester Screening 33%
• Second Trimester 33%
• Intermediate-risk Group 33%
• Pregnant Women 16%
• Clinical Implementation 16%
• Fetus 16%
• Singleton Pregnancy 16%
• Conventional Strategy 16%
• Nuchal Translucency 16%
• Line Assay 16%
• Screening for Trisomy 21 16%

Medicine and Dentistry

• Trisomy 100%
• Cell-Free DNA 100%
• Trisomy 21 44%
• False Positive Result 44%
• Trisomy 18 33%
• Trisomy 13 33%
• Cell-Free DNA Testing 33%
• First Trimester Pregnancy 22%
• Second Trimester Pregnancy 22%
• Intermediate Risk Population 22%
• High Risk Population 11%
• Nuchal Translucency Measurement 11%